CA2320717C - Method for the treatment of diseases or disorders of the inner ear - Google Patents
Method for the treatment of diseases or disorders of the inner ear Download PDFInfo
- Publication number
- CA2320717C CA2320717C CA002320717A CA2320717A CA2320717C CA 2320717 C CA2320717 C CA 2320717C CA 002320717 A CA002320717 A CA 002320717A CA 2320717 A CA2320717 A CA 2320717A CA 2320717 C CA2320717 C CA 2320717C
- Authority
- CA
- Canada
- Prior art keywords
- inner ear
- cells
- p27kip1
- nucleic acid
- regeneration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000003027 ear inner Anatomy 0.000 title claims abstract description 61
- 238000000034 method Methods 0.000 title abstract description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 18
- 201000010099 disease Diseases 0.000 title abstract description 9
- 208000035475 disorder Diseases 0.000 title abstract description 9
- 230000001953 sensory effect Effects 0.000 claims abstract description 66
- 108010016777 Cyclin-Dependent Kinase Inhibitor p27 Proteins 0.000 claims abstract description 17
- 102000000577 Cyclin-Dependent Kinase Inhibitor p27 Human genes 0.000 claims abstract description 17
- 230000035755 proliferation Effects 0.000 claims abstract description 8
- 230000004936 stimulating effect Effects 0.000 claims abstract 4
- 210000004027 cell Anatomy 0.000 claims description 99
- 150000007523 nucleic acids Chemical class 0.000 claims description 27
- 108020004707 nucleic acids Proteins 0.000 claims description 26
- 102000039446 nucleic acids Human genes 0.000 claims description 26
- 230000008929 regeneration Effects 0.000 claims description 25
- 238000011069 regeneration method Methods 0.000 claims description 25
- 210000002768 hair cell Anatomy 0.000 claims description 24
- 230000009471 action Effects 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 206010011878 Deafness Diseases 0.000 claims description 5
- 208000016354 hearing loss disease Diseases 0.000 claims description 4
- 230000000692 anti-sense effect Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims 6
- 108020004999 messenger RNA Proteins 0.000 claims 6
- 230000010370 hearing loss Effects 0.000 claims 3
- 231100000888 hearing loss Toxicity 0.000 claims 3
- 230000001737 promoting effect Effects 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 2
- 229940123587 Cell cycle inhibitor Drugs 0.000 abstract description 20
- 230000006378 damage Effects 0.000 abstract description 20
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 abstract description 11
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 abstract description 11
- 229940126074 CDK kinase inhibitor Drugs 0.000 abstract description 5
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 abstract description 5
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 description 29
- 108090000623 proteins and genes Proteins 0.000 description 21
- 241000124008 Mammalia Species 0.000 description 17
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 230000002401 inhibitory effect Effects 0.000 description 15
- 230000008569 process Effects 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 210000004209 hair Anatomy 0.000 description 13
- 210000003477 cochlea Anatomy 0.000 description 12
- 210000000981 epithelium Anatomy 0.000 description 11
- 230000032823 cell division Effects 0.000 description 9
- 230000003993 interaction Effects 0.000 description 9
- 230000022131 cell cycle Effects 0.000 description 8
- 238000011813 knockout mouse model Methods 0.000 description 7
- 210000002985 organ of corti Anatomy 0.000 description 7
- 239000013603 viral vector Substances 0.000 description 7
- 108020005544 Antisense RNA Proteins 0.000 description 6
- 102000002554 Cyclin A Human genes 0.000 description 6
- 108010068192 Cyclin A Proteins 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 239000003184 complementary RNA Substances 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 5
- 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 230000011278 mitosis Effects 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000000067 inner hair cell Anatomy 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 108020004491 Antisense DNA Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 206010011891 Deafness neurosensory Diseases 0.000 description 2
- 208000027601 Inner ear disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 2
- 229960004821 amikacin Drugs 0.000 description 2
- 239000003816 antisense DNA Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- BICGOULMPJLRQV-MYINAIGISA-N 1-[(2s,4s,5r)-2-bromo-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO)O[C@@]1(Br)N1C(=O)NC(=O)C=C1 BICGOULMPJLRQV-MYINAIGISA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 206010011903 Deafness traumatic Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 241000272496 Galliformes Species 0.000 description 1
- 206010048865 Hypoacusis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000017119 Labyrinth disease Diseases 0.000 description 1
- 208000002946 Noise-Induced Hearing Loss Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000000721 basilar membrane Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000354 cell of hensen Anatomy 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- -1 lipid compounds Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008756 pathogenetic mechanism Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000000645 stria vascularis Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000001720 vestibular Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19807426.3 | 1998-02-23 | ||
| DE19807426A DE19807426A1 (de) | 1998-02-23 | 1998-02-23 | Verfahren zur Behandlung von Erkrankungen oder Störungen des Innenohrs |
| PCT/EP1999/001153 WO1999042088A2 (de) | 1998-02-23 | 1999-02-23 | Verfahren zur behandlung von erkrankungen oder störungen des innenohrs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2320717A1 CA2320717A1 (en) | 1999-08-26 |
| CA2320717C true CA2320717C (en) | 2009-03-24 |
Family
ID=7858563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002320717A Expired - Fee Related CA2320717C (en) | 1998-02-23 | 1999-02-23 | Method for the treatment of diseases or disorders of the inner ear |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7087581B1 (enExample) |
| EP (1) | EP1056467B1 (enExample) |
| JP (1) | JP2002503687A (enExample) |
| AT (1) | ATE250936T1 (enExample) |
| AU (1) | AU763868B2 (enExample) |
| CA (1) | CA2320717C (enExample) |
| DE (2) | DE19807426A1 (enExample) |
| DK (1) | DK1056467T3 (enExample) |
| ES (1) | ES2211055T3 (enExample) |
| PT (1) | PT1056467E (enExample) |
| WO (1) | WO1999042088A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2325198A1 (en) | 1999-06-01 | 2011-05-25 | Baylor College Of Medicine | Compositions and methods for the therapeutic use of an atonal-associated sequence |
| DE10027777A1 (de) * | 2000-06-07 | 2001-12-13 | Otogene Ag | Transfektionsverfahren |
| CA2412764C (en) * | 2000-07-11 | 2014-06-03 | Sound Pharmaceuticals Incorporated | Stimulation of cellular regeneration and differentiation in the inner ear |
| JP4533144B2 (ja) | 2002-10-02 | 2010-09-01 | アンジェスＭｇ株式会社 | 聴覚機能障害用医薬 |
| EP1585523B1 (en) * | 2002-12-17 | 2008-10-01 | Centre National De La Recherche Scientifique (Cnrs) | Use of purine derivatives for inducing differentiation of supernumerary hair cells and deiters' cells in the developing organ of corti for treating deafness |
| EP2293800B1 (en) | 2008-06-06 | 2016-10-05 | Quark Pharmaceuticals, Inc. | Compositions and methods for treatment of ear disorders |
| DE102010007281A1 (de) * | 2010-02-08 | 2011-08-11 | EMC microcollections GmbH, 72070 | Neue Aminoalkyl-oxazol- und Aminoalkyl-thiazolcarbonsäureamide und ihre Anwendung zur Stimulation der endogenen situ Regeneration von Haarsinneszellen im Corti'schen Organ des Innenohres beim Säuger |
| RU2480195C1 (ru) * | 2011-11-02 | 2013-04-27 | Федеральное государственное учреждение "Российский научный центр восстановительной медицины и курортологии Федерального агентства по здравоохранению и социальному развитию РФ" (ФГУ "РНЦВМиК Росздрава РФ") | Способ лечения заболеваний внутреннего уха |
| EP2802657B1 (en) | 2012-01-12 | 2018-05-02 | Quark Pharmaceuticals, Inc. | Combination therapy for treating hearing and balance disorders |
| WO2013134022A1 (en) * | 2012-03-05 | 2013-09-12 | Wake Forest University Health Sciences | Regeneration of inner ear cells |
| TWI710635B (zh) | 2014-10-09 | 2020-11-21 | 美商珍維克公司 | 編碼人類無調同源物-1(hath1)之腺病毒載體 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19528388A1 (de) * | 1995-08-02 | 1997-02-06 | Hans Peter Prof Dr Med Zenner | Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs |
| EP0866716A4 (en) | 1995-11-13 | 2002-05-02 | Cambridge Neuroscience Inc | METHOD FOR TREATING DISORDERS OF THE NON-VISUAL SENSORIC EPITHEL |
| US5962224A (en) * | 1995-12-19 | 1999-10-05 | Dana-Farber Cancer Institute | Isolated DNA encoding p62 polypeptides and uses therefor |
| AU3591597A (en) | 1996-06-28 | 1998-01-21 | Regents Of The University Of California, The | Transformation and genetherapy of cells of the inner ear |
| AU4600297A (en) | 1996-09-27 | 1998-04-17 | Trustees Of The University Of Pennsylvania, The | Novel methods for inducing proliferation in auditory receptor epithelium |
| US6043221A (en) * | 1997-07-30 | 2000-03-28 | Amgen Inc. | Method for preventing and treating hearing loss using a neuturin protein product |
-
1998
- 1998-02-23 DE DE19807426A patent/DE19807426A1/de not_active Withdrawn
-
1999
- 1999-02-23 DE DE59907195T patent/DE59907195D1/de not_active Expired - Fee Related
- 1999-02-23 PT PT99910259T patent/PT1056467E/pt unknown
- 1999-02-23 WO PCT/EP1999/001153 patent/WO1999042088A2/de not_active Ceased
- 1999-02-23 DK DK99910259T patent/DK1056467T3/da active
- 1999-02-23 CA CA002320717A patent/CA2320717C/en not_active Expired - Fee Related
- 1999-02-23 ES ES99910259T patent/ES2211055T3/es not_active Expired - Lifetime
- 1999-02-23 EP EP99910259A patent/EP1056467B1/de not_active Expired - Lifetime
- 1999-02-23 US US09/622,719 patent/US7087581B1/en not_active Expired - Lifetime
- 1999-02-23 AU AU29281/99A patent/AU763868B2/en not_active Ceased
- 1999-02-23 AT AT99910259T patent/ATE250936T1/de not_active IP Right Cessation
- 1999-02-23 JP JP2000532105A patent/JP2002503687A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999042088A3 (de) | 2000-03-02 |
| EP1056467A2 (de) | 2000-12-06 |
| WO1999042088A2 (de) | 1999-08-26 |
| DE59907195D1 (de) | 2003-11-06 |
| ES2211055T3 (es) | 2004-07-01 |
| AU2928199A (en) | 1999-09-06 |
| ATE250936T1 (de) | 2003-10-15 |
| PT1056467E (pt) | 2004-02-27 |
| DE19807426A1 (de) | 1999-10-14 |
| CA2320717A1 (en) | 1999-08-26 |
| US7087581B1 (en) | 2006-08-08 |
| AU763868B2 (en) | 2003-07-31 |
| JP2002503687A (ja) | 2002-02-05 |
| EP1056467B1 (de) | 2003-10-01 |
| DK1056467T3 (da) | 2004-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kole et al. | Activating transcription factor 3 (ATF3) protects retinal ganglion cells and promotes functional preservation after optic nerve crush | |
| RU2288718C2 (ru) | Лекарственные средства, содержащие ингибиторы человеческой h-sgk киназы, контролирующей клеточный объем | |
| Rubel et al. | A brief history of hair cell regeneration research and speculations on the future | |
| Handley et al. | Synapse dysfunction of layer V pyramidal neurons precedes neurodegeneration in a mouse model of TDP-43 proteinopathies | |
| Zhang et al. | Selenium restores synaptic deficits by modulating NMDA receptors and selenoprotein K in an Alzheimer's disease model | |
| US10330671B2 (en) | Modulation of synaptic maintenance | |
| Jørgensen et al. | Cometin is a novel neurotrophic factor that promotes neurite outgrowth and neuroblast migration in vitro and supports survival of spiral ganglion neurons in vivo | |
| CA2320717C (en) | Method for the treatment of diseases or disorders of the inner ear | |
| Libertini | The programmed aging paradigm: how we get old | |
| Akil et al. | Virally mediated overexpression of glial-derived neurotrophic factor elicits age-and dose-dependent neuronal toxicity and hearing loss | |
| CN110339360B (zh) | 瞬时受体电位阳离子通道trpv3在研制预防或治疗银屑病药物中的应用 | |
| Li | Deer antler renewal gives insights into mammalian epimorphic regeneration | |
| WO2024251289A1 (en) | Use of kinase domain m7ck of trpm7 in preparation of drug for treating alzheimer's disease | |
| Kustermann et al. | Survival, excitability, and transfection of retinal neurons in an organotypic culture of mature zebrafish retina | |
| Bitsche et al. | Neurotrophic receptors as potential therapy targets in postnatal development, in adult, and in hearing loss-affected inner ear | |
| Zhang et al. | Functional optic tract rewiring via subtype-and target-specific axonal regeneration and presynaptic activity enhancement | |
| Kelley | Cellular commitment and differentiation in the cochlea: potential advances using gene transfer | |
| Petrova et al. | Protrudin functions as a scaffold in the endoplasmic reticulum to support axon regeneration in the adult central nervous system | |
| KR101766441B1 (ko) | 헌팅틴 유전자의 뇌 시공간 특이적 발현 방법 및 이를 이용한 동물 모델 | |
| Qamar | Creating an in vivo model of Progressive Supranuclear Palsy | |
| PANE et al. | The Upper Limb Cardiopulmonary Exercise Test in Friedrich Ataxia Patients | |
| Dali et al. | Tanycyte-mediated synapse pruning shapes hypothalamic circuits controlling metabolism | |
| Brooks | Pou3f4-Expressing Otic Mesenchyme Cells: A Novel Influence for Cochlear Spiral Ganglion Neuron Survival | |
| Chiara et al. | Neuronal hemoglobin induces α-synuclein cleavage and loss of dopaminergic neurons | |
| WO2024164318A1 (zh) | Gch1抑制剂在制备用于预防和治疗听力损伤的药物中的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |